BTK and allergic disease: Oral inhibitors of Bruton’s tyrosine kinase (BTKis), which are currently FDA-approved for the treatment of B cell malignancies, broadly inhibit the FcεRI pathway in human mast cells and basophils and therefore may be effective allergen-independent therapies for a variety of allergic diseases.